AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a trailblazing clinical-stage biopharmaceutical company speciali...
The completion of Cohort 3 marks a significant milestone, with six participants receiving therapy with 67Cu-SAR-bisPSMA at the highest sing...
In an effort to bridge testing gaps and facilitate targeted therapies for EOC patients, Labcorp conducted two seminal studies, illustrating the profound im...
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the Europea...
Novo Holdings, a leading global life sciences investor, has announced its participation in a significant €30M Series A financing round for Asgard Ther...
Bayer and Aignostics GmbH, a pioneering force in computational pathology, have unveiled a landmark strategic partnership aimed at revolutionizing precision...
In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal a...
Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancr...
With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk of developing can...
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneous...
– Proceeds will be used to complete clinical demonstration trials of the lead candidate drug RNDP-001 for the treatment of Parkinson's di...
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking dat...
“We are excited to commence patient enrollment for the PoC human clinical trial, marking a significant milestone in our mission to revolution...
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announ...
© 2024 Biopharma Boardroom. All Rights Reserved.
